Pyxis Oncology Inc (NASDAQ:PYXS)’s traded shares stood at 0.62 million during the last session, with the company’s beta value hitting 1.01. At the close of trading, the stock’s price was $1.59, to imply a decrease of -1.85% or -$0.03 in intraday trading. The PYXS share’s 52-week high remains $6.85, putting it -330.82% down since that peak but still an impressive 6.29% since price per share fell to its 52-week low of $1.49. The company has a valuation of $94.55M, with an average of 0.94 million shares in intraday trading volume over the past 10 days and average of 1.25 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Pyxis Oncology Inc (PYXS), translating to a mean rating of 1.22. Of 2 analyst(s) looking at the stock, 0 analyst(s) give PYXS a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.29.
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
After registering a -1.85% downside in the last session, Pyxis Oncology Inc (PYXS) has traded red over the past five days. The 5-day price performance for the stock is 3.25%, and -10.17% over 30 days. With these gigs, the year-to-date price performance is -11.67%. Short interest in Pyxis Oncology Inc (NASDAQ:PYXS) saw shorts transact 6.08 million shares and set a 3.13 days time to cover.
The extremes give us $7 and $10 for target low and target high price respectively. As such, PYXS has been trading -528.93% off suggested target high and -340.25% from its likely low.
Pyxis Oncology Inc (PYXS) estimates and forecasts
Looking at statistics comparing Pyxis Oncology Inc share performance against respective industry, we note that the company has outperformed competitors. Pyxis Oncology Inc (PYXS) shares are -51.96% down over the last 6 months, with its year-to-date growth rate higher than industry average at 44.32% against 16.40%.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -118.72% for the past 5-year period. While 2024 is set for a 41.34% return in earnings, projections for the next 5 years are at 34.60% annually.
PYXS Dividends
Pyxis Oncology Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
Pyxis Oncology Inc insiders hold 24.54% of total outstanding shares, with institutional holders owning 56.55% of the shares at 74.94% float percentage. In total, 56.55% institutions holds shares in the company, led by DEEP TRACK CAPITAL, LP. As of 2024-06-30, the company held over 4.18 million shares (or 8.1578% of shares), all amounting to roughly $13.85 million.
The next major institution holding the largest number of shares is LAURION CAPITAL MANAGEMENT LP with 3.86 million shares, or about 7.5282% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $12.78 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Pyxis Oncology Inc (PYXS) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 1.29 shares. This is just over 2.18% of the total shares, with a market valuation of $2.06 million. Data from the same date shows that the other fund manager holds a little less at 1.23, or 2.07% of the shares, all valued at about 1.96 million.
